<?xml version="1.0" encoding="UTF-8"?>
<p>Treatment systems need to facilitate uninterrupted access to the most effective medications for OUD treatment: methadone and buprenorphine (
 <xref rid="r2-1210" ref-type="bibr">2</xref>). Regarding methadone, federal agencies relaxed requirements for physical examinations and allowed extended medication supply for stable patients (
 <xref rid="r3-1210" ref-type="bibr">3</xref>). We need to rapidly expand methadone delivery via mobile teams (for example, repurposed syringe service programs) for quarantined patients. Opioid treatment programs—federally regulated facilities that primarily dispense methadone—should increase use of buprenorphine because of its safer pharmacologic properties and formulations that can be dosed thrice weekly and monthly. Federal agencies should leverage funds from a recent settlement about misuse of regulatory procedures by a buprenorphine manufacturer (
 <xref rid="r4-1210" ref-type="bibr">4</xref>) to address financial barriers to buprenorphine provided through opioid treatment programs.
</p>
